Cytokinetics Inc (NASDAQ: CYTK) on Tuesday, plunged -3.52% from the previous trading day, before settling in for the closing price of $65.6. Within the past 52 weeks, CYTK’s price has moved between $29.31 and $70.98.
Annual sales at Healthcare sector company slipped by -20.02% over the past five years. The company achieved an average annual earnings per share of -20.65%. With a float of $119.93 million, this company’s outstanding shares have now reached $122.12 million.
Let’s look at the performance matrix of the company that is accounted for 498 employees.
Cytokinetics Inc (CYTK) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cytokinetics Inc is 1.91%, while institutional ownership is 115.56%. The most recent insider transaction that took place on Dec 22 ’25, was worth 1,322,800. In this transaction Director of this company sold 20,000 shares at a rate of $66.14, taking the stock ownership to the 32,444 shares. Before that another transaction happened on Dec 22 ’25, when Company’s Director proposed sale 20,000 for $62.72, making the entire transaction worth $1,254,400.
Cytokinetics Inc (CYTK) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.26 earnings per share (EPS) for the period falling under the consensus outlook (set at -1.17) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.40% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Cytokinetics Inc (CYTK) is currently performing well based on its current performance indicators. A quick ratio of 6.88 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 88.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.31, a number that is poised to hit -1.55 in the next quarter and is forecasted to reach -5.76 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Cytokinetics Inc (NASDAQ: CYTK) saw its 5-day average volume 3.37 million, a positive change from its year-to-date volume of 1.93 million. As of the previous 9 days, the stock’s Stochastic %D was 47.49%.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 79.81%, which indicates a significant increase from 33.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.98 in the past 14 days, which was higher than the 2.44 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $62.73, while its 200-day Moving Average is $45.59. Nevertheless, the first resistance level for the watch stands at $65.04 in the near term. At $66.78, the stock is likely to face the second major resistance level. The third major resistance level sits at $68.30. If the price goes on to break the first support level at $61.77, it is likely to go to the next support level at $60.25. The third support level lies at $58.51 if the price breaches the second support level.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
Market capitalization of the company is 7.74 billion based on 122,265K outstanding shares. Right now, sales total 18,470 K and income totals -589,530 K. The company made 1,940 K in profit during its latest quarter, and -306,180 K in sales during its previous quarter.
